Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies
Scrambler therapy is a non-invasive neurocutaneous electrical pain intervention, effective for the treatment of neuropathic pain. Currently, few data about the efficacy of this treatment in cancer pain induced by skeletal and visceral metastases are available. The aim of this single-center case series is to evaluate the efficacy of scrambler therapy in reducing this kind of cancer pain after failure of standard treatments, including pharmacological therapies and radiation therapy.
Twenty-five consecutive patients underwent scrambler therapy individually delivered by MC5-A Calmare for 10 daily sessions each of 30–40 min. Pain was measured by a numeric rating scale at baseline, as well as before and after each treatment session.
One hundred percent of patients reached a pain relief ≥50 %. Pain score was reduced from 8.4 at baseline to 2.9 after treatment, with a mean pain relief of 89 %. The sleeping hours improved from 4.4 ± 1.2 to 7.5 ± 1.1. The duration of pain control by scrambler therapy was 7.7 ± 5.3 weeks. No adverse events were observed.
Scrambler therapy does not present toxicity and allows opioids dosage reduction, and it is also a repeatable treatment. Present novel data support that scrambler therapy seems to be effective for the treatment of cancer pain. Further evaluation in randomized and controlled clinical trials should be performed to confirm our findings.
KeywordsScrambler therapy Untreatable cancer pain Metastatic bone and visceral pain Electroanalgesia Calmare®
- 4.Arai YP, Nishihara M, Yamamoto Y, Arakawa M, Kondo M, Suzuki C, Kinoshita A, Kambara K, Ikemoto T (2015) Dorsal root ganglion pulsed radiofrequency for the management of intractable vertebral metastatic pain: a case series. Pain Med 16(5):1007–1012. doi:10.1111/pme.12629 CrossRefPubMedGoogle Scholar
- 5.Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, Lachance DH, Liu H, Shelerud RA, Cheville AL, Loprinzi CL (2015) Pilot evaluation of scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer 23(4):943–951. doi:10.1007/s00520-014-2424-8 PubMedCentralCrossRefPubMedGoogle Scholar
- 6.Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag 43(1):87–95. doi:10.1016/j.jpainsymman.2011.03.015 CrossRefGoogle Scholar
- 10.Coyne PJ, Wan W, Dodson P, Swainev C, Smith TJ (2013) A trial of scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. J Pain Palliat Care Pharmacother 27(4):359–364. doi:10.3109/15360288.2013.847519 PubMedCentralCrossRefPubMedGoogle Scholar
- 11.Campbell TC, Nimunkar AJ, Retseck J, Eickhoff JC, Backonja M, Cleary JF, Kwekkeboom KL, Yen TY (2013) A randomized, doubleblind study of “Scrambler” therapy versus sham for painful chemotherapy-induced peripheral neuropathy (CIPN). J Clin Oncol 31: suppl abstr 963Google Scholar
- 12.Marineo G (2003) Untreatable pain resulting from abdominal cancer: new hope from biophysics? J Pancreas 4(1):1–10Google Scholar
- 15.Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R, National Comprehensive Cancer Network (2013) Adult cancer pain. J Natl Compr Canc Netw 11(8):992–1022PubMedGoogle Scholar